Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non‐melanoma skin cancer in an at‐risk population: A cohort study
- 20 January 2012
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 27 (2), 385-389
- https://doi.org/10.1111/j.1440-1746.2011.06865.x
Abstract
The thiopurines azathioprine and 6-mercaptopurine are effective in the management of patients with inflammatory bowel disease (IBD) in whom aminosalicylates, antibiotics and corticosteroids have failed to induce or maintain remission. Long-term use of these agents has been linked to a greatly increased risk of non-melanoma skin cancer and lymphatic cancer in organ transplant recipients. There is some evidence to suggest that IBD patients receiving thiopurines might be at increased risk of cancer. Our aim was to determine the incidence of cancer in a cohort of patients with IBD managed in our clinic, and to relate this to thiopurine exposure. We conducted a retrospective study based on the clinical and pathology records of patients attending a specialist IBD clinic at Groote Schuur Hospital, Cape Town, South Africa between 1960 and 2007. We analyzed the records of 1084 patients. A total of 123 subjects (11.5%) had received thiopurine therapy. Cancer was identified in 51 patients (4.7%), including colorectal cancer (15 patients), melanoma (two patients), non-melanoma skin cancer (seven patients) and non-Hodgkin's lymphoma (five patients). A diagnosis of non-melanoma skin cancer was significantly associated with thiopurine exposure (odds ratio 5.0, 95% confidence interval 1.1-22.8). Six of seven non-melanoma skin cancers occurred in Caucasian patients, with a highly significant association with thiopurine use (odds ratio 12.4, 95% confidence interval 2.3-67.4). Patients with IBD who receive thiopurines are at increased risk of non-melanoma skin cancer. The risk is highest in Caucasian patients, and is negligible in other groups.Keywords
This publication has 32 references indexed in Scilit:
- Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2010
- Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2009
- Exposing the Weaknesses: A Systematic Review of Azathioprine Efficacy in Ulcerative ColitisDigestive Diseases and Sciences, 2007
- Management of inflammatory bowel disease in adultsJournal of Digestive Diseases, 2007
- Azathioprine in dermatology: The past, the present, and the futureJournal of the American Academy of Dermatology, 2006
- Azathioprine and UVA Light Generate Mutagenic Oxidative DNA DamageScience, 2005
- Drug methylation in cancer therapy: lessons from the TPMT polymorphismOncogene, 2003
- Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is lowGut, 2000
- Non-Hodgkin's lymphoma after immunosuppressive therapyGut, 2000